Has Katy Ticona received payments from drug or device companies?

Yes. Drug and device makers reported $8,244 in general payments to Katy Ticona across 342 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Katy Ticona did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Katy Ticona come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Katy Ticona

Hematology & Oncology · Brooklyn, NYNPI 1669867966

Payments from drug & device makers

$8,244in general payments, 2019–2025

Across 342 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$790
Bristol Myers Squibb$540
Incyte Corporation$509
Eisai Inc.$495
Daiichi Sankyo Inc.$475
Lilly USA, LLC$422
plus $5K from 54 others

What the payments were for

Food & beverage$7,99097%
Education$2543%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	39	$790
Bristol Myers Squibb	22	$540
Incyte Corporation	19	$509
Eisai Inc.	22	$495
Daiichi Sankyo Inc.	18	$475
Lilly USA, LLC	18	$422
Novartis	21	$410
Regeneron Healthcare Solutions, Inc.	16	$400
Gilead(2 entities)	12	$298
Merck	13	$294
AstraZeneca(2 entities)	9	$227
Beigene USA, Inc.	8	$225
Johnson & Johnson	8	$215
Sanofi	3	$179
Pharmacosmos Therapeutics Inc.	8	$175
Seagen Inc.	7	$157
Takeda Pharmaceuticals U.S.A., Inc.	5	$137
Jazz Pharmaceuticals Inc.	5	$130
Pharmaessentia USA Corporation	4	$116
GSK	4	$106
AVEO Pharmaceuticals, Inc.	2	$101
Puma Biotechnology, Inc.	4	$81
Array Biopharma Inc	3	$72
Fennec Pharmaceuticals, Inc.	2	$71
E.r. Squibb & Sons, L.L.C.	4	$69
Janssen Scientific Affairs, LLC	2	$68
Sun Pharmaceutical Industries Inc.	2	$66
Exelixis Inc.	4	$62
Tempus AI, Inc	2	$60
Legend Biotech USA Inc.	2	$59
Organon	3	$58
Agios Pharmaceuticals, Inc.	2	$58
Beone Medicines USA, Inc.	2	$58
CTI Biopharma Corp.	3	$57
Sobi, Inc	3	$54
Boehringer Ingelheim	2	$54
Novocure Inc.	2	$52
Stemline Therapeutics Inc.	2	$51
Sumitomo Pharma America, Inc.	2	$50
Servier Pharmaceuticals LLC	2	$50
Amgen	2	$49
Kyowa Kirin, Inc.	2	$48
Accord Healthcare, Inc.	2	$47
Telix Pharmaceuticals	2	$43
Deciphera Pharmaceuticals Inc.	2	$43
Caris MPI, Inc.	1	$41
Alnylam Pharmaceuticals Inc.	2	$40
Genentech USA, Inc.	2	$40
Global Blood Therapeutics, Inc.	2	$34
Morphosys, US Inc.	2	$33
Dendreon Pharmaceuticals LLC	1	$31
Foundation Medicine, Inc.	1	$29
Pharmacyclics LLC, An Abbvie Company	1	$29
GE HealthCare	1	$28
Azurity Pharmaceuticals, Inc.	1	$25
AbbVie	1	$24
EMD Serono, Inc.	1	$22
Myovant Sciences Inc.	1	$22
Karyopharm Therapeutics Inc.	1	$21
Taiho Oncology, Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LIBTAYO$120

How this compares

$8,244 in reported general payments places this provider in the 55th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York →

Medicare billing

Part B allowed, 2024

$133,372

Medicare patients

Services billed

9,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	13	$120
Letrozole	11	$86

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Brooklyn

Vicky MakkerNew York$27.1M
Alison MoskowitzNew York$22.7M
Ajai ChariNew York$22.4M
Yelena JanjigianNew York$16.9M
Alexander LesokhinNew York$11.9M
John MascarenhasNew York$11.8M
Maria PalombaNew York$11.6M
Richard ZunigaBabylon$10.9M
Scott TagawaNew York$10.3M
Mohammad Abdul HayNew York$9.9M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →